in Drug Discovery

  • Anti-Cancer Drugs
  • Anti-Infective Agents
  • Anti-inflammatory and Immunomodulating Agents
  • Cardiovascular and Hematologic Drugs
  • In silico Methods and Artificial Intelligence for Drug Discovery
  • Neurological Drugs

  • (current)Journal
  • About
  • Articles
  • Research topics
  • For authors
    • Why submit?
    • Fees
    • Article types
    • Author guidelines
    • Review guidelines
    • Submission checklist
    • Contact editorial office
    • Submit your manuscript
  • Editorial board
  • Article alerts

Articles

  • Online articles
  • Latest
  • Most viewed
  • Tier-climbing
Loading..

Scope

Frontiers in Drug Discovery is an open access journal dedicated to publishing rigourously peer-reviewed studies focusing on drug discovery and the development lifecycle, from the identification of drug entities, to the design and development of new candidate medications and therapies.

Read more

Editorial Board

  •  

This journal has no chief editors.

Loading..

Research Topics

  •  

Loading..
  • Scope & Mission
  • Facts
  • Submission
  • Open Access Statement
  • Copyright Statement
  • Quality
  • Contact

Scope & Mission

Frontiers in Drug Discovery is an Open Access journal publishing rigorously peer-reviewed research across disciplines and associated cutting edge technologies that are critical to the discovery and development of new drugs and therapies. Field Chief Editor Bruno Villoutreix at INSERM is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. The covered drugs encompass a wide variety of agents, including small molecules and biologics. 

Coverage includes:

  • Small molecules including short peptides, nucleic acids, macrocycles
  • Biologics including therapeutic proteins, antibodies, cell therapies
  • Experimental low, medium and high-throughput approaches
  • In vitro models for early-stage drug discovery such as 3D cell cultures, patient-derived organoids
  • A broad range of in silico methods from molecular modeling to artificial intelligence
  • Big data and smart data, knowledge discovery and actionable knowledge
  • Novel targets, pathways and molecular mechanisms in the health and disease states
  • Novel therapeutic strategies
  • Drug repurposing
  • Drug combination
  • In silico and in vitro ADME-Tox studies to assist drug discovery
  • Computational-Chemistry-Biology-Medicine continuum
  • National and International Drug Discovery and Development Platforms and Networks
  • Integration of skills and technologies, Transcending silo mentality and promoting efficiency 

We also welcome editorial submissions that explore topics such as personalized and stratified medicine, pharmacoeconomics, project mining, management and strategic planning, ecosystem mapping, public-private partnerships, academic drug discovery and translational medicine, training and education, empowering citizen and patients to contribute to the drug discovery process and increasing the awareness of politicians and mass medias about drug discovery


Frontiers in Drug Discovery is a member of the Committee on Publication Ethics.

Facts

Short Name: Front. Drug. Discov.

Abbreviation: fddsv

Electronic ISSN: 2674-0338

Indexed in: CLOCKSS, CrossRef, Google Scholar, OpenAIRE

PMCID: NA

Submission

Frontiers in Drug Discovery is composed of the following Specialty Sections:

Anti-Cancer Drugs

Anti-Infective Agents

Anti-inflammatory and Immunomodulating Agents

Cardiovascular and Hematologic Drugs

In silico Methods and Artificial Intelligence for Drug Discovery

Neurological Drugs

The specialty sections of Frontiers in Drug Discovery welcome submission of the following article types: Brief Research Report, Case Report, Clinical Trial, Community Case Study, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Policy and Practice Reviews, Policy Brief, Protocols, Review, Systematic Review and Technology and Code.

When submitting a manuscript to Frontiers in Drug Discovery, authors must submit the material directly to one of the specialty sections. Manuscripts are peer-reviewed by the Associate and Review Editors of the respective specialty section.

Open Access Statement

Copyright Statement

Quality

Contact

Frontiers Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41 (0)21 510 17 00
Fax +41 (0)21 510 17 01

drugdiscovery.editorial.office@frontiersin.org

Frontiers Support
Tel +41 (0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org

    • All sections
    • Anti-Cancer Drugs
    • Anti-Infective Agents
    • Anti-inflammatory and Immunomodulating Agents
    • Cardiovascular and Hematologic Drugs
    • In silico Methods and Artificial Intelligence for Drug Discovery
    • Neurological Drugs
    • All Roles
    • Field Chief Editors
    • Specialty Chief Editors
    • Associate Editors
    • Review Editors
  • Editor(s) found
  • By role
  • Most viewed
  • Most publications

There are no results to display.

Loading..

Click on any of the keywords to find further editors related to it.
    • Article(s) found
    • Latest
    • Most viewed
    Loading..

    This journal has no articles.

    There are no articles to display. Please try changing the filters.

      • All stages
      • Submission open
      • Submission closed
      • Ebook available
    • Research Topic(s) found
    • Latest
    • Most viewed

    Loading..

    Loading..

    Loading..

    Loading..

    Loading..

    Loading..

    Loading..

    Contact Editorial Office

    Frontiers Editorial Office

    Avenue du Tribunal Fédéral 34
    CH – 1005 Lausanne
    Switzerland

    Tel +41(0)21 510 17 40
    Fax +41 (0)21 510 17 01

    For all queries regarding manuscripts in Review and potential conflicts of interest, please contact drugdiscovery.editorial.office@frontiersin.org

    For queries regarding Research Topics, Editorial Board applications, and journal development, please contact drugdiscovery@frontiersin.org

    Frontiers IT HelpDesk

    Tel +41(0)21 510 17 10
    Fax +41 (0)21 510 17 01

    For technical issues, please visit our Frontiers Help Center, or contact our IT HelpDesk team at support@frontiersin.org

    Loading..